AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

(2020) Jacob J. Adashek et al.   ONCOLOGIST

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ovarian Cancer Immunotherapy: Turning up the Heat

(2019) Eleonora Ghisoni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors

(2019) Helei Hou et al.   Cancer Cell International

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

(2019) Douglas D. Fang et al.   Journal for ImmunoTherapy of Cancer

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype

(2018) Christopher D. Wiley et al.   Scientific Reports

Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model

(2018) Jibin Li et al.   MEDICAL SCIENCE MONITOR

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

(2018) Yiyi Yan et al.   Frontiers in Immunology

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53

(2015) K. W. Yoon et al.   SCIENCE

p53 in the Myeloid Lineage Modulates an Inflammatory Microenvironment Limiting Initiation and Invasion of Intestinal Tumors

(2015) Xue-Yan He et al.   Cell Reports

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses

(2014) Qiang Zou et al.   NATURE IMMUNOLOGY

Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer

(2014) E Brighenti et al.   ONCOGENE

Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research

(2013) Michael S. Anglesio et al.   PLoS One

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

(2008) Hiroaki Itamochi et al.   CANCER SCIENCE